whytestocks
5 years ago
News: $PTCT PTC Therapeutics Announces New Real-World Analysis Demonstrating Translarna(TM) (ataluren) Slows Disease Progression in Patients with Duchenne Muscular Dystrophy
SOUTH PLAINFIELD, N.J. , Oct. 4, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that data from STRIDE,* the first international registry for patients with Duchenne muscular dystrophy due to a nonsense mutation receiving Translarnaä (ataluren), de...
In case you are interested PTCT - PTC Therapeutics Announces New Real-World Analysis Demonstrating Translarna(TM) (ataluren) Slows Disease Progression in Patients with Duchenne Muscular Dystrophy
chainma1l
8 years ago
PTC Therapeutics announces its JV w/ Roche (RHHBY) and the SMA Foundation initiated a clinical study (FIREFISH) in infants with Type I SMA
FIREFISH is a two-part study.
โขPart one is an open-label, dose escalation study in at least 8 infants for a minimum of 4 weeks. ?The primary objective of part one is to assess the safety profile of RG7916 in infants and determine the dose for part two.
โขPart two is an open-label, single-arm study in !40 infants with Type I SMA for 24 months, followed by an open-label extension. ?The primary objective of part two is to assess the efficacy of RG7916 at the selected dose over a 12-month treatment period.
โขA trial in childhood onset (Type II/III) SMA patients, SUNFISH, is currently enrolling the dose escalation portion of the study.
โขCommencement of the pivotal portion of either study will trigger a $20 mln milestone payment to co from Roche (RHHBY).
This was announced a while back, but PTC announced the initiation of the study today. This started in 2006, so hopefully things can move along to help the kids who are affected.
http://www.prnewswire.com/news-releases/ptc-therapeutics-announces-initiation-of-firefish-study-in-infant-type-i-sma-patients-300386262.html
Options2Wealth
8 years ago
Great call on SMMT!
My only regret is that after first reading your post, I only bought a very small position for tracking purpose only...Today when I opened my account and saw SMMT double, my first reaction was that Ameritrade must be having a system glitch. Wish I had done some due diligence after taking a tracking position...
Since you have clearly done your research on SMMT, where do you see this going...
I apologize for the Off-Topic post.
On PTCT, I expect the stock to resume its upward move. When it prints $17.01, it will be ready to close the yawning $10 gap above. So I am looking for a $14 move, a double from here(!), by the end of the year. First stop: $17.01
contax